Why we still need drugs for COVID ‐19 and can't just rely on vaccines-Reference-Cited by-同舟云学术

Why we still need drugs for COVID ‐19 and can't just rely on vaccines

Published:2021-12-30 Issue:2 Volume:27 Page:109-111
ISSN:1323-7799
Container-title:Respirology
language:en
Short-container-title:Respirology

Author:

Robinson Bruce W. S.¹²³⁴^ORCID,Tai Anna¹²³^ORCID,Springer Kyle⁵

Affiliation:

1. School of Medicine The University of Western Australia Perth Western Australia Australia

2. Department of Respiratory Medicine Sir Charles Gairdner Hospital Perth Western Australia Australia

3. Institute for Respiratory Health Perth Western Australia Australia

4. Early Digital/Drug Intervention for COVID‐19 Treatment (EDICT), Institute for Respiratory Health, University of Western Australia Perth Western Australia Australia

5. Perth USAsia Centre The University of Western Australia Perth Western Australia Australia

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/resp.14199

Reference8 articles.

1. World Health Organization. WHO Coronavirus Disease (COVID‐19) Dashboard. [cited 2021 Dec 19]. Available from:https://covid19.who.int/

2. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

3. CallawayE.Heavily Mutated Coronavirus Variant Puts Scientists on Alert. Nature News. [cited 2021 Dec 19]. Available from:https://www.nature.com/articles/d41586-021-03552-w.

4. WHO. Preparing for Pandemics. [cited 2021 Dec 19]. Available from:https://www.who.int/westernpacific/activities/preparing-for-pandemics.

5. Johns Hopkins University & Medicine Coronavirus Resource CenterIndia. [cited 2021 Dec 19]. Available from:https://coronavirus.jhu.edu/region/india.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis, in vitro and in silico evaluation of gallamide and selenogallamide derivatives as inhibitors of the SARS‐CoV‐2 main protease;Archiv der Pharmazie;2024-08-15

2. Identification of potential antiviral lead inhibitors against SARS-CoV-2 main protease: Structure-guided virtual screening, docking, ADME, and MD Simulation based approach;Artificial Intelligence Chemistry;2023-12

3. Applicability of Redirecting Artemisinins for New Targets;Global Challenges;2023-10-27

4. Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19;Expert Review of Anti-infective Therapy;2023-08-01

5. Identification of Potential Antiviral Lead Inhibitors Against Sars-Cov-2 Main Protease: Structure-Guided Virtual Screening, Docking, Adme, and Md Simulation Based Approach;2023